Eva Domingo‐Doménech

机构：Duran i Reynals Hospital · ORCID：0000-0001-8907-090X

发表论文 242 篇 · 总被引 4989 次 · h-index 34

代表论文

• Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial (2025 · The Lancet · 被引 18)
• Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up (2025 · Blood Cancer Journal · 被引 5)
• A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone ( BrEPEM ) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial (2025 · British Journal of Haematology · 被引 3)
• Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma (2025 · Blood Advances · 被引 2)
• Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma (2025 · Future Oncology · 被引 1)
• Asparaginase Hypersensitivity Reactions in NK/T-Cell Lymphomas (2025 · Clinics and Practice · 被引 1)